Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin effects on cardiovascular risk markers in women with polycystic ovary syndrome
2009-015729-35Phase 4Completed
- Sponsor
- Hull University Teaching Hospitals
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of laropiprant in polycystic ovary syndrome (PCOS), sponsored by Hull University Teaching Hospitals. Primary endpoints: Improvement of lipid profile, Insulin resistance and hs-CRP and 1 more. Started Oct 2009; status: completed.
02
Drugs
laropiprant
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on 2009-015729-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015729-35.